Siemens Healthineers has begun preparing its in vitro diagnostics business to operate as Olyrian Diagnostics, giving a large testing operation a distinct identity through a transition expected to finish by mid-2028.
The Olyrian name will be introduced in stages alongside the parent company’s planned change of name to Healthineers. The diagnostics operation will stay within Siemens Healthineers while the transition is underway. The company said there had been no changes as of Nov. 5 to products, services, contracts, service levels or customer contacts.
Siemens Healthineers said its Diagnostics unit produces more than 16 billion tests each year. Its work includes laboratory automation, informatics and point-of-care testing. In the quarter ended Sept. 30, 2026, Diagnostics posted a 4.2% comparable revenue decline and an adjusted EBIT margin of 5.4%, according to the company’s fourth-quarter fiscal 2026 results.
Siemens Healthineers said the separate identity is intended to give the operation a distinct market presence focused on in vitro diagnostics. The business took shape after acquisitions in 2006 and 2007, the company said; the acquired organizations’ histories reach back as far as 1884.
Reuters reported that the business had faced weakness in China after healthcare reforms. Siemens Healthineers did not cite that issue as a reason for the carve-out in its announcement. CEO Bernd Montag said the move was part of an effort to sharpen the company’s portfolio and strengthen its core while preparing Diagnostics for its next phase. Sharon Bracken, head of Diagnostics for Siemens Healthineers, called Olyrian the business’s “next chapter.”
The company has yet to outline how the carve-out would be structured or who would own the operation after the transition. It expects the change to be completed by mid-2028.
